The Venture Codex Logo

The Venture Codex

Alloy Therapeutics

275 Second Avenue Suite 200, Waltham, MA, 02451, United States

Overview

Democratizing access to drug discovery platforms and services.

Founded

2017

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Seed
Series A

Geographic focus

United States

Sector focus

Biopharma
Biotechnology
Life Science
Therapeutics

Investment portfolio

5rounds
NAMEDATESIZE
Wheeler Bio
Mar 2025Led
$35 MSeries A
Wheeler Bio
Apr 2023Participated
$31 MSeries A
Vernal Biosciences
Jun 2022Participated
$21 MOther Equity
Mytide Therapeutics
Mar 2022Led
$7 MSeries A
Wheeler Bio
Jan 2022Led
$14 MSeed
Wheeler Bio
Mar 2025Led
$35 MSeries A
Wheeler Bio
Apr 2023Participated
$31 MSeries A
Vernal Biosciences
Jun 2022Participated
$21 MOther Equity
Mytide Therapeutics
Mar 2022Led
$7 MSeries A
Wheeler Bio
Jan 2022Led
$14 MSeed
5
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Alloy Therapeutics: 5 funding rounds are recorded in the selected participation categories.All available history.
Alloy Therapeutics: 5 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed10
Series A21
Other Equity01

Monthly Deal Activity

Alloy Therapeutics: 5 deals are recorded across 58 months.All available history.
Alloy Therapeutics: 5 deals are recorded across 58 months. All available history
MonthDeals
Jan '221
Feb '220
Mar '221
Apr '220
May '220
Jun '221
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '231
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '251
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Alloy Therapeutics: Health & Life Sciences is the largest displayed sector by deal count (5 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Alloy Therapeutics: Health & Life Sciences is the largest displayed sector by deal count (5 deals). All available history
SectorDeals
Health & Life Sciences5

Deal Size Distribution

Alloy Therapeutics: 5 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Alloy Therapeutics: 5 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M1
$10M-$25M2
$25M-$50M2
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Alloy Therapeutics: United States has the largest recorded deal count among the displayed regions (5 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Alloy Therapeutics: United States has the largest recorded deal count among the displayed regions (5 deals). All available history
RegionDeals
United States5
Alloy Therapeutics: 16 co-investors are shown, with ATUM sharing 2 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Alloy Therapeutics: 16 co-investors are shown, with ATUM sharing 2 recorded deals. All available history
Co-investorShared deals
ATUM2
Charles River Laboratories2
Echo Investment Capital2
Floating Point2
Ampersand Capital Partners1
Dynamk Capital1
Echo1
Germin8 Ventures1
Mitsubishi Corporation1
Pine Ridge Ventures1
Plains Ventures1
Presbyterian Health Foundation1
Russell Westbrook Enterprises1
Seagull Capital1
The round was co-led by1
Uncommon Denominator1

Investment Strategy

Alloy Therapeutics: Led accounts for 60% and participating for 40% of round participation.All available history.
Alloy Therapeutics: Led accounts for 60% and participating for 40% of round participation. All available history
CategoryDeals (count)Share (%)
Led360%
Participating240%
Alloy Therapeutics: Single-lead accounts for 33% and co-led for 67% of lead dynamics.All available history.
Alloy Therapeutics: Single-lead accounts for 33% and co-led for 67% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead133%
Co-led267%

Team

Christian Cobaugh

Chief Executive Officer of Genetic Medicines Division

Errik Anderson

Founder and CEO

John Lippincott

Senior Vice President Therapeutic Discovery Strategies

Martin Leach

Chief Operating Officer

Michael Schmidt

Chief Scientific Officer

Richard Shimkets

SVP Genetics and New Technologies

Trier Bryant

President of Venture Studio, 82VS